Connect with Us at the Upcoming Events

Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at the 13th Annual World ADC San Diego and the 13th Annual World Multispecific Summit in September, the 10th Annual Immuno-Oncology Summit in October, and the Antibody Engineering & Therapeutics (US) 2022 in December for expert consultation on your drug discovery projects. Shoot an email to arrange an in-person meeting!

Book a Meeting

Anti-Human MASP-2 Monoclonal Antibody (clone 8B5) -10 mg (CAT#: CB-P480-K) Datasheet

Product Type
Antibody
Description
The monoclonal antibody 8B5 reacts with the CCP1/2-SP fragment of human MASP-2. MASP-2 is a trypsin-like serine protease and plays an important rol in the initiation of the MBL complement activation pathway. Three pathways of complement activation have been reported: the antibody-dependent classical pathway, the antibody-independent alternative pathway and the lectin pathway. Activation of each pathway involves formation of serine protease complexes, which results in activation of the central complement component C3. In the lectin pathway, mannose binding-lectin (MBL)-associated serine proteases (MASPs) form complexes with polymeric lectin molecules which are involved in pattern recognition. Upon binding of the recognition molecules to carbohydrates on the surface of micro organisms, MASPs are converted to their active forms and initiate complement activation. Three types of human MASP have been reported. MASP-1, MASP-2 and MASP-3. Mannan-binding lectin (MBL) and ficolins, in complex with MBL-associated serin proteases (MASPs), are capable of activation the complement system, thus mediating the destruction of infectious agents. MASP-2 cleaves C4 and C2 and is crucial for the activation of downstream complement components.
Size
100 µg

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK